Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab for Primary Sjögren's Syndrome
NCT04093531Phase 1Completed
- Sponsor
- University of Rochester
- Start
- Jan 2020
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ustekinumab in primary Sjögren's syndrome, sponsored by University of Rochester. Primary endpoint: European League Against Rheumatism Sjögren's Syndrome Patient Reported Index at 24 weeks. Started Jan 2020; status: completed.
02
Drugs
ustekinumab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT04093531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04093531.